Recombinant Gal-1 allergy environment immunologic tolerance induction model and establishing method

Abstract

The invention belongs to the field of medical treatment and discloses a recombinant Gal-1 allergy environment immunologic tolerance induction model and an establishing method. The induction model can induce antigen-specificity regulatory T cells out and recover antigen-specificity immunologic tolerance in a body of a patient, so that allergy reaction is inhibited; under allergy reaction environment, a TNF-alpha content in the body is increased, Gal-1 expression is inhibited, and anti-TNF-alpha antibody is applied to improve Gal-1; the Gal-1 can promote LLPC to be differentiated into Breg, and the anti-TNF-alpha antibody, SIT and Gal-1 are jointly applied to promoting antigen-specificity immunologic tolerance to recover.

Description

technical field [0001] The invention belongs to the medical field, and in particular relates to a recombinant Gal-1 allergic environment immune tolerance induction model and a method for establishing it. Background technique [0002] Immune tolerance refers to the specific immune non-response state produced by the body's immune system after accepting the action of a certain antigen. Individuals who have developed immune tolerance to a specific antigen do not develop an immune response or cannot develop an immune response that can be detected by conventional methods after being stimulated by the antigen again. Therefore, the normal immune tolerance mechanism is very important to maintain the health of the body. The mechanism of immune tolerance is still not very clear. Although the international and domestic research on the factors that impair immune tolerance has made rapid progress in recent years, the restoration of the established immune tolerance damage and the recover...

AI Technical Summary

Problems solved by technology

[0003] In summary, the problems in the prior art are: diseases caused by abnormal immune tolerance have a significant negative impact on human health and social economy, and the curative effect is not good; restoring antigen specificity in individuals with abnormal immune tolerance However, it is more difficult to resist immune tolerance; it is not sure whether the triple agent can also promote the differentiation of antigen-specific LLPC into antigen-specific Breg in vivo, and the combination and ratio of Gal-1, SIT and anti-TNF-α antibody in the triple agent and promote Relevance of abnormal intestinal mucosal immune tolerance recovery

Images